Factors affecting R0 resection of colorectal cancer with synchronous peritoneal metastases: a multicenter prospective observational study by the Japanese Society for Cancer of the Colon and Rectum
- 33 Downloads
In Japan, R0 resection has been recommended for colorectal cancer patients with peritoneal metastases confined to the adjacent peritoneum and those with a few metastases to the distant peritoneum. R0 resection for M1c disease has drawn attention in Western countries and is currently considered an acceptable therapeutic option in the US National Comprehensive Cancer Network guidelines. However, clinical factors that affect the choice of R0 resection are unknown.
This multicenter, prospective, observational study was conducted by the Japanese Society for Cancer of the Colon and Rectum. Colorectal cancer patients with synchronous peritoneal metastases were enrolled at 28 institutions in Japan from October 2012 to December 2016. To determine factors affecting R0 resection and R1 resection with intended R0 resection, stepwise logistic regression analyses were performed on clinical factors including age, sex, performance status (PS), body mass index, peritoneal cancer index (PCI) score, presence of ascites, presence of distant metastases, and primary tumor site.
R0/R1 resection was performed in 36 (31/5; 25%) of 146 patients. No distant metastases [odds ratio (OR) 52.9; 95% confidence interval (CI) 13.3–210.1; p < 0.0001], low PCI score (1–6) (OR 20.0; 95% CI 4.8–83.4; p < 0.0001), and high PS (0) (OR 2.40; 95% CI 0.66–8.68; p = 0.18) were independent factors affecting R0/R1 resection. PCI score and PS were also independent factors affecting R0/R1 resection in M1c patients without non-peritoneal distant metastases (n = 59).
Distant metastases, PCI score, and PS are three factors which affect R0 resection for M1c disease.
KeywordsPeritoneal metastasis Colorectal cancer R0 resection Peritoneal cancer index score
Area under the curve
Hyperthermic intraperitoneal chemotherapy
National Comprehensive Cancer Network
Peritoneal cancer index
Receiver operating characteristic
- TNM classification
This study is based on data collected from 28 hospitals participating in a multicenter, prospective, observational study of CRC with synchronous peritoneal metastases conducted by the JSCCR. We thank all the participating patients and their families, as well as investigators and operation staff members. We also thank Masamichi Yasuno (Tokyo Medical and Dental University), Masayuki Ohue (Osaka International Cancer Institute), Hideo Yano (National Center for Global Health and Medicine), Soichiro Ishihara (University of Tokyo), Keiji Koda (Teikyo University Chiba Medical Center), Hirotoshi Kobayashi (Tokyo Metropolitan Hiroo Hospital), Fumio Baba (Kumamoto University), Yoshiharu Sakai (Kyoto University), Yojiro Hashiguchi (Teikyo University), Akio Yamaguchi (University of Fukui), Masato Kusunoki (Mie University), Naohiro Tomita (Hyogo College of Medicine), Tadahiko Masaki (Kyorin University), Yoshito Akagi (Kurume University), Mitsuyoshi Ota (Yokohama City University Medical Center), Kenichi Hakamada (Hirosaki University), and Yasuhiro Kodera (Nagoya University).
None to report.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Franko J, Shi Q, Meyers JP et al (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol 17(12):1709–1719. https://doi.org/10.1016/S1470-2045(16)30500-9 CrossRefPubMedGoogle Scholar
- 2.UICC (2017) TNM classification of malignant tumours, 8th edn. Wiley, New YorkGoogle Scholar
- 6.Sugarbaker PH, Ryan DP (2012) Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 13(8):e362–369. https://doi.org/10.1016/S1470-2045(12)70210-3 CrossRefPubMedGoogle Scholar
- 8.Watanabe T, Muro K, Ajioka Y, Japanese Society for Cancer of the C, Rectum et al (2018) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23(1):1–34. https://doi.org/10.1007/s10147-017-1101-6 CrossRefPubMedGoogle Scholar
- 10.Watanabe T, Itabashi M, Shimada Y, Japanese Society for Cancer of the C, Rectum et al (2012) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 17(1):1–29. https://doi.org/10.1007/s10147-011-0315-2 CrossRefPubMedGoogle Scholar
- 11.Watanabe T, Itabashi M, Shimada Y, Japanese Society for Cancer of the C, Rectum et al (2015) Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20(2):207–239. https://doi.org/10.1007/s10147-015-0801-z CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Noura S, Ohue M, Ito Y et al (2016) New staging system for colorectal cancer patients with synchronous peritoneal metastasis in accordance with the japanese classification of colorectal carcinoma: a multi-institutional study. Dig Surg 33(1):66–73. https://doi.org/10.1159/000442027 CrossRefPubMedGoogle Scholar
- 15.Shida D, Tsukamoto S, Ochiai H et al (2018) Long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 25(1):173–178. https://doi.org/10.1245/s10434-017-6133-7 CrossRefPubMedGoogle Scholar
- 18.JSCCR (2018) Japanese classification of colorectal, appendiceal, and anal carcinoma, 9th edn. Kanehara & Co., Ltd, TokyoGoogle Scholar
- 20.Bushati M, Rovers KP, Sommariva A et al (2018) The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the peritoneal surface oncology group international (PSOGI). Eur J Surg Oncol 44(12):1942–1948. https://doi.org/10.1016/j.ejso.2018.07.003 CrossRefPubMedGoogle Scholar
- 23.Arnold D, Lueza B, Douillard JY et al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28(8):1713–1729. https://doi.org/10.1093/annonc/mdx175 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Kobayashi H, Kotake K, Funahashi K, Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the C, Rectum et al (2014) Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol 49(4):646–654. https://doi.org/10.1007/s00535-013-0820-3 CrossRefPubMedGoogle Scholar
- 27.Kobayashi H, Kotake K, Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the C, Rectum (2014) Enhancing the objectivity of the Japanese classification of peritoneal metastases from colorectal cancer. Jpn J Clin Oncol 44(10):898–902. https://doi.org/10.1093/jjco/hyu114 CrossRefPubMedGoogle Scholar